Skip to main content

Table 4 Mean (standard deviation) of Short form-36 Health Survey version 2 and CLDQ in the two groups during and between episodes of unconjugated hyperbilirubinemia

From: The frequency, clinical course, and health related quality of life in adults with Gilbert’s syndrome: a longitudinal study

Scores (norm)* Subjects with Gilbert Syndrome) (101 subjects; n = 83 with GS and 18 with GS and treated HCV) Control subjects (n = 100) P value
During jaundice episode In between jaundice episodes   During jaundice episode In between jaundice episodes
SF-6D preference 0.72 ± 0.12 0.77 ± 0.12 0. ± 0.11 < 0.0001** 0.278
SF-36v2
 PF 82.5 ± 7.35 89.952 ± 2.41 90.10 ± 2.40 0.0001** 0.051
 RP 90.19 ± 4.2 89.19 ± 4.2 90. ± 1.4 0.06 0.81
 BP 81.3 ± 3.5 83.03 ± 2.8 82.63 ± 6.36 0.07 0.56
 GH 49.27 ± 14.5 52.64 ± 10.3 53.24 ± 9.11 0.02 * 0.66
 VT 55.34 ± 4.61 59.81 ± 4.18 60.35 ± 3.617 0.0001** 0.33
 SF 87.16 ± 9.73 92.74 ± 15.2 92.47 ± 14.9 0.0031** 0.9
 RE 80.61 ± 7.24 88.39 ± 5.21 88.53 ± 8.56 < 0.0001** 0.88
 MH 71.9 ± 3.6 72.6 ± 3.04 72.10 ± 4.3 0.38 0.71
 PCS 45.00 ± 12.9 47.927 ± 9.21 48.81 ± 8.7 0.02 0.48
MCS 49.81 ± 3.9 49.71 ± 3.82 50.87 ± 4.31 0.07 0.07
CLDQ
 AS 5.48 ± 1.83 6.2 ± 1.64 6.23 ± 1.55 0.012* 0.58
 FA 4.80 ± 1.25 5.37 ± 1.36 5.72 ± 1.03 <  0.0001** 0.04*
 SS 5.02 ± 0.82 5.712 ± 1.224 5.82 ± 1.0 < 0.0001 ** 0.47
 AC 5.87 ± 1.84 6.25 ± 1.33 6.55 ± 1.41 0.004 ** 0.12
 EF 5.231 ± 1.74 5.73 ± 1.41 5.84 ± 1.43 0.007 * 0.59
 WO 5.41 ± 1.26 5.83 ± 1.54 5.90 ± 1.632 0.02* 0.72
 Overall 5.32 ± 1.36 5.82 ± 0.89 5.92 ± 1.63 0.006** 0.64
  1. GS Gilbert syndrome, HCV hepatitis C virus infection
  2. *Significant difference between the two study groups (P < 0.05). ** Highly significant difference between the two study groups during the jaundice attack or between jaundice attacks (P < 0.01, 0.001)
  3. AC activity, AS abdominal symptoms, BP bodily pain, EF emotional function, FA fatigue, GH general health, MCS Mental Component Summary Score, MH mental health, PCS Physical Component Summary Score, PF physical functioning, RE Role Emotional, RP role physical, SF social functioning, SS systemic symptoms, VT vitality, WO worry
  4. During jaundice episodes, significant differences were observed between subjects with GS ans controls in: SF-6D, the SF-36v2 domains: PF, GH, VT, SF. RE and all CLDQ domains.
  5. In between the hyperbilirubinemia attacks no significant differences in SF-6D, SF-36v2 domains or CLDQ domains except for a slight difference in FA